u/lulmagician · 288d agono track record yet
“balls deep into this, been stacking position for a few days”
Did a thing - IBRX
IBRX is entering a high-growth phase driven by ANKTIVA's successful commercialization and regulatory expansion. The drug achieved 700% YoY revenue growth in 2025, secured accelerated approval in Saudi Arabia for both bladder and lung cancer, and has a de-risked pipeline with BCG-naïve trials ahead of schedule, positioning the company for substantial TAM expansion.
At post $5.52Now $8.29+50.2% since postedas of Oct 30, 4:45 PM ET
1d—
3d—
1w+16.8%
1m+7.7%
3m+31.3%
6m+40.0%
1y—